{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:15Z","timestamp":1793321775678,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11102-022-01252-w","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T09:02:43Z","timestamp":1658134963000},"page":"754-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel approaches to bone comorbidity in Cushing\u2019s disease: an update"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5598","authenticated-orcid":false,"given":"Stefano","family":"Frara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Doga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-550X","authenticated-orcid":false,"given":"Paola","family":"Loli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-8161","authenticated-orcid":false,"given":"Felipe F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"12","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"Frara S, Melin Uygur M, di Filippo L et al (2022) High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J Clin Endocrinol Metab 107(7):e2843\u2013e2850. https:\/\/doi.org\/10.1210\/clinem\/dgac183","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319\u20131328. https:\/\/doi.org\/10.1007\/s00198-007-0394-0","journal-title":"Osteoporos Int"},{"issue":"8","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437\u2013447. https:\/\/doi.org\/10.1038\/s41574-020-0341-0","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","volume":"35","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, di Filippo L et al (2021) Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35(2):101515. https:\/\/doi.org\/10.1016\/j.beem.2021.101515","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s1043-2760(00)00234-4","volume":"11","author":"F Manelli","year":"2000","unstructured":"Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11(3):79\u201385. https:\/\/doi.org\/10.1016\/s1043-2760(00)00234-4","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265\u2013276. https:\/\/doi.org\/10.1038\/nrendo.2013.5","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1210\/jc.2011-1600","volume":"96","author":"AL Skversky","year":"2011","unstructured":"Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML (2011) Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001\u20132006. J Clin Endocrinol Metab 96(12):3838\u20133845. https:\/\/doi.org\/10.1210\/jc.2011-1600","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","volume":"54","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Formenti AM, Adler RA et al (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3):603\u2013611. https:\/\/doi.org\/10.1007\/s12020-016-1146-8","journal-title":"Endocrine"},{"issue":"4","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bone.2003.11.026","volume":"34","author":"E Canalis","year":"2004","unstructured":"Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34(4):593\u2013598. https:\/\/doi.org\/10.1016\/j.bone.2003.11.026","journal-title":"Bone"},{"issue":"8","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA et al (2017) (2017) American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Rheumatol 2017 Nov; 69(11):2246]. Arthritis Rheumatol. 69(8):1521\u20131537. https:\/\/doi.org\/10.1002\/art.40137","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Burattin A, Nuzzo M et al (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152(2):199\u2013205. https:\/\/doi.org\/10.1530\/eje.1.01841","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","volume":"41","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC et al (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr 41(4):990\u20131000. https:\/\/doi.org\/10.1016\/j.clnu.2021.11.014","journal-title":"Clin Nutr"},{"issue":"6","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1530\/EJE-16-0289","volume":"175","author":"I Chiodini","year":"2016","unstructured":"Chiodini I, Vainicher CE, Morelli V et al (2016) Mechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol 175(6):R265\u2013R282. https:\/\/doi.org\/10.1530\/EJE-16-0289","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/cen.12812","volume":"83","author":"CV dos Santos","year":"2015","unstructured":"dos Santos CV, Vieira Neto L, Madeira M et al (2015) Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol (Oxf) 83(4):468\u2013474. https:\/\/doi.org\/10.1111\/cen.12812","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s40618-020-01496-y","volume":"44","author":"T Apayd\u0131n","year":"2021","unstructured":"Apayd\u0131n T, Yavuz DG (2021) Assessment of non-traumatic vertebral fractures in Cushing\u2019s syndrome patients. J Endocrinol Invest 44(8):1767\u20131773. https:\/\/doi.org\/10.1007\/s40618-020-01496-y","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1210\/jcem.83.6.4880","volume":"83","author":"I Chiodini","year":"1998","unstructured":"Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 83(6):1863\u20131867. https:\/\/doi.org\/10.1210\/jcem.83.6.4880","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41(1):58\u201369. https:\/\/doi.org\/10.1007\/s12020-011-9570-2","journal-title":"Endocrine"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11657-015-0244-1","volume":"10","author":"ZE Belaya","year":"2015","unstructured":"Belaya ZE, Hans D, Rozhinskaya LY et al (2015) The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome. Arch Osteoporos 10:44. https:\/\/doi.org\/10.1007\/s11657-015-0244-1","journal-title":"Arch Osteoporos"},{"issue":"4","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440\u2013488. https:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr Rev"},{"issue":"3","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tem.2020.12.004","volume":"32","author":"AM Formenti","year":"2021","unstructured":"Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A (2021) Effects of medical treatment of prostate cancer on bone health. Trends Endocrinol Metab 32(3):135\u2013158. https:\/\/doi.org\/10.1016\/j.tem.2020.12.004","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1210\/clinem\/dgaa738","volume":"106","author":"L di Filippo","year":"2021","unstructured":"di Filippo L, Formenti AM, Doga M, Pedone E, Rovere-Querini P, Giustina A (2021) Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J Clin Endocrinol Metab 106(2):e602\u2013e614. https:\/\/doi.org\/10.1210\/clinem\/dgaa738","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanov\u00e0","year":"2006","unstructured":"Tauchmanov\u00e0 L, Pivonello R, Di Somma C et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91(5):1779\u20131784. https:\/\/doi.org\/10.1210\/jc.2005-0582","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1210\/jc.2003-031413","volume":"89","author":"I Chiodini","year":"2004","unstructured":"Chiodini I, Guglielmi G, Battista C et al (2004) Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 89(5):2237\u20132241. https:\/\/doi.org\/10.1210\/jc.2003-031413","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","volume":"15","author":"ME Randazzo","year":"2012","unstructured":"Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, Loli P (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15(2):193\u2013201. https:\/\/doi.org\/10.1007\/s11102-011-0306-3","journal-title":"Pituitary"},{"issue":"1","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/eje.0.1460051","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Lindholm J, J\u00f8rgensen JO et al (2002) Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome. Eur J Endocrinol 146(1):51\u201356. https:\/\/doi.org\/10.1530\/eje.0.1460051","journal-title":"Eur J Endocrinol"},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/TCRM.S12952","volume":"6","author":"T Mancini","year":"2010","unstructured":"Mancini T, Porcelli T, Giustina A (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag. 6:505\u2013516. https:\/\/doi.org\/10.2147\/TCRM.S12952","journal-title":"Ther Clin Risk Manag."},{"issue":"3","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"dgz054","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"Chiloiro S, Giampietro A, Frara S et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. J Clin Endocrinol Metab. 105(3):dgz054. https:\/\/doi.org\/10.1210\/clinem\/dgz054","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(22)00135-8","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Castinetti F, Gadelha M et al (2022) Osilodrostat for the treatment of Cushing\u2019s disease: efficacy, stability, and persistence\u2014authors\u2019 reply. Lancet Diabetes Endocrinol 10(6):385\u2013387. https:\/\/doi.org\/10.1016\/S2213-8587(22)00135-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1210\/jcem.86.12.8066","volume":"86","author":"E Canalis","year":"2001","unstructured":"Canalis E, Giustina A (2001) Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86(12):5681\u20135685. https:\/\/doi.org\/10.1210\/jcem.86.12.8066","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253\u2013259. https:\/\/doi.org\/10.1016\/j.bone.2006.02.005","journal-title":"Bone"},{"issue":"5","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S et al (2017) Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177(5):R231\u2013R248. https:\/\/doi.org\/10.1530\/EJE-17-0154","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","volume":"25","author":"A Scillitani","year":"2014","unstructured":"Scillitani A, Mazziotti G, Di Somma C et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25(2):441\u2013446. https:\/\/doi.org\/10.1007\/s00198-013-2588-y","journal-title":"Osteoporos Int"},{"issue":"12","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"e10417","DOI":"10.1002\/jbm4.10417","volume":"4","author":"A Giustina","year":"2020","unstructured":"Giustina A, Bouillon R, Binkley N et al (2020) Controversies in vitamin D: a statement from the third international conference. JBMR Plus. 4(12):e10417. https:\/\/doi.org\/10.1002\/jbm4.10417","journal-title":"JBMR Plus."},{"issue":"4","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11154-021-09693-7","volume":"22","author":"JP Bilezikian","year":"2021","unstructured":"Bilezikian JP, Formenti AM, Adler RA et al (2021) Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22(4):1201\u20131218. https:\/\/doi.org\/10.1007\/s11154-021-09693-7","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","volume":"2","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F et al (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2(9):e1911080. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11080","journal-title":"JAMA Netw Open."},{"issue":"10","key":"1252_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/art.1780371014","volume":"37","author":"GM Hall","year":"1994","unstructured":"Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37(10):1499\u20131505. https:\/\/doi.org\/10.1002\/art.1780371014","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/ard.2010.143453","volume":"70","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ying KY, To CH et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70(5):778\u2013784. https:\/\/doi.org\/10.1136\/ard.2010.143453","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1252_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1365-2265.1998.00486.x","volume":"48","author":"C Di Somma","year":"1998","unstructured":"Di Somma C, Colao A, Pivonello R et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing\u2019s disease. Clin Endocrinol (Oxf) 48(5):655\u2013662. https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00486.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1252_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11102-005-1051-2","volume":"7","author":"T Mancini","year":"2004","unstructured":"Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing\u2019s syndrome and bone. Pituitary 7(4):249\u2013252. https:\/\/doi.org\/10.1007\/s11102-005-1051-2","journal-title":"Pituitary"},{"issue":"3","key":"1252_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cen.12299","volume":"80","author":"M Zilio","year":"2014","unstructured":"Zilio M, Barbot M, Ceccato F et al (2014) Diagnosis and complications of Cushing\u2019s disease: gender-related differences. Clin Endocrinol (Oxf) 80(3):403\u2013410. https:\/\/doi.org\/10.1111\/cen.12299","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1252_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bonr.2015.03.001","volume":"2","author":"SY Kim","year":"2015","unstructured":"Kim SY, Davydov O, Hans D, Bockman R (2015) Insights on accelerated skeletal repair in Cushing\u2019s disease. Bone Rep. 2:32\u201335. https:\/\/doi.org\/10.1016\/j.bonr.2015.03.001","journal-title":"Bone Rep."},{"issue":"1","key":"1252_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.beem.2017.03.002","volume":"31","author":"AM Formenti","year":"2017","unstructured":"Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A (2017) Growth hormone deficiency in treated acromegaly and active Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 31(1):79\u201390. https:\/\/doi.org\/10.1016\/j.beem.2017.03.002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"1252_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jcem.80.1.7829600","volume":"80","author":"A Giustina","year":"1995","unstructured":"Giustina A, Bussi AR, Jacobello C, Wehrenberg WB (1995) Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80(1):122\u2013129. https:\/\/doi.org\/10.1210\/jcem.80.1.7829600","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1252_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF (2020) Pituitary tumors centers of excellence. Endocrinol Metab Clin North Am 49(3):553\u2013564. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01252-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T09:24:47Z","timestamp":1666430687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01252-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01252-w","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"30 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval from institutional ethics committee is not required for a review paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Author Andrea Giustina is consultant to company Abiogen SpA, Recordati SpA and Takeda Pharmaceutical Co; Author Andrea Giustina is grant recipient from Pfizer and Takeda Pharmaceutical Co.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interest"}},{"value":"An Informed Consent is not applicable for a review paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}